Jacobs Journal of Cancer Science and Research

Targeted therapy for Chondrosarcoma

*Timothy Allen
Department Of Oncology, Enter For Excellence In Research And Development, United States

*Corresponding Author:
Timothy Allen
Department Of Oncology, Enter For Excellence In Research And Development, United States
Email:Timothy.Allen@gapsos.com

Published on: 2016-11-30

Abstract

Primary malignant bone tumors occur 1/100,000, of which 17-24% consists of chondrosarcoma. Unfortunately, the cause is unknown, but there have been several risks factors accused of causing the disease. Targeted therapy is a cancer specific treatment alternative to chemotherapy and radiation therapy. Its goal is to control and inhibit cancer promoting pathways as well as activating patient’s own immune system to fight the tumor. The patient’s immune system is stimulated by exposing synthetic immune molecules into their system. In this paper, we discuss the potential causes of chondrosarcomas, the pathophysiology of the disease, and potential ways to cure the disease using different targeted therapy techniques.

Keywords

Bone cancer; Chondrosarcoma; Targeted Therapy; TKIs; mTOR Inhibitors

Introduction

Chondrosarcoma (CHS) is a cancer composed of cells derived from transformed cells that produce cartilage. Chondrosarcoma is the third most common primary malignancy diagnosed in the bone after myeloma and osteosarcoma. Most of these tumors grow slowly and metastasize occasionally. They have an excellent prognosis after adequate surgery. Due to the involvement of the extracellular matrix, a low percentage of dividing cells, and poor vascularity, these tumors are resistant to chemo and radiotherapy. Wide surgical excision remains the best available treatment option. Few patients recur with metastatic disease, and up to 13% of recurrent chondrosarcomas are of a higher grade than the original neoplasm. In adults, over 40% of primary bone cancers are chondrosarcoma, which is less than 0.2% of all types of cancer. In children and teenagers (those younger than 20 years), osteosarcoma (56%) and Ewing sarcoma (34%) are much more common than chondrosarcoma (6%).